Dexketoprofen

Drug Profile

Dexketoprofen

Alternative Names: Arveles; D 1158; Desketo; Dexketoprofen trometamol; Dexketoprofen tromethamine; Dextroketoprofen; Enangel; Enantyum; Keral; Ketesse; LM 1158; Nosatel; Quiralam; Quirgel; S-ketoprofen; Stadium; Sympal; Viaxal

Latest Information Update: 29 Sep 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Menarini
  • Developer Berlin Chemie; Celltech Group; Istituto Lusofarmaco; Malesci; Menarini
  • Class Nonsteroidal anti-inflammatories; Phenylpropionates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Prostaglandin synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Inflammation; Musculoskeletal pain; Pain

Most Recent Events

  • 01 May 2014 Menarini completes a phase I bioavailability trial in volunteers in United Kingdom (NCT02209454)
  • 01 Apr 2014 Menarini initiates a phase I bioavailability trial in volunteers in United Kingdom (NCT02209454)
  • 30 Dec 2003 A case report has been added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top